US00D966300S

(12) **United States Design Patent**
Dobak, III et al.

(10) **Patent No.: US D966,300 S**
(45) **Date of Patent: ** Oct. 11, 2022**

(54) **COMPUTER DISPLAY PANEL WITH A GRAPHICAL USER INTERFACE FOR A DERMATOLOGY REPORT**

(71) Applicant: **DermTech, Inc.**, La Jolla, CA (US)

(72) Inventors: **John Daniel Dobak, III**, La Jolla, CA (US); **Sarah Dion**, San Diego, CA (US); **Burkhard Jansen**, La Jolla, CA (US); **Jane Bue**, Vista, CA (US); **Claudia Ibarra**, Carlsbad, CA (US)

(73) Assignee: **DERMTECH, INC.**, La Jolla, CA (US)

(**) Term: **15 Years**

(21) Appl. No.: **29/770,786**

(22) Filed: **Feb. 16, 2021**

(51) **LOC (13) Cl.** **14-04**

(52) **U.S. Cl.**
USPC **D14/486**

(58) **Field of Classification Search**
USPC D14/485–495
CPC G06F 3/048; G06F 3/0481; G06F 3/04812; G06F 3/04815; G06F 3/04817; G06F 3/0482; G06F 3/0483; G06F 3/0484; G06F 3/04842; G06F 3/04845; G06F 3/04847; G06F 3/0485; G06F 3/04855; G06F 3/0486; G06F 3/04886; G06Q 30/00; G06Q 30/02; G06Q 30/0237; G06Q 30/0238; G06Q 30/0239; H03J 1/00; H03J 1/0008; H03J 1/0016; H03J 1/0025; H04N 5/00; H04N 5/08; H04N 5/14; H04N 5/222; H04N 5/225; H04N 5/232; H04N 5/23222; H04N 5/23293; H04N 5/232933; H04N 5/232935; H04N 5/445; H04N 5/44504; H04N 5/45; H04N 21/00; H04N 21/234; H04N 21/431; H04N 21/4312; H04N 21/4314; H04N 21/4316; H04N 21/4532; H04N 21/4622; H04N 21/47; H04N 21/478; H04N 21/482;
(Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,122,947 A 10/1978 Falla
5,190,049 A 3/1993 Briggs et al.
(Continued)

FOREIGN PATENT DOCUMENTS

WO WO-0010579 A1 3/2000
WO WO-03001985 A2 1/2003
(Continued)

OTHER PUBLICATIONS

Cerda et al. Geometry and Physics of Wrinkling. Phys Rev Lett 90(7):074302 (2003).
(Continued)

Primary Examiner — Christian P. McLean
(74) *Attorney, Agent, or Firm* — Wilson Sonsini Goodrich & Rosati

(57) **CLAIM**

The ornamental design for a computer display panel with a graphical user interface for a dermatology report, as shown and described.

DESCRIPTION

FIG. **1** is a front view of a computer display panel with a graphical user interface for a dermatology report, showing our new design; and,

FIG. **2** is a front view of another embodiment of a computer display panel with a graphical user interface for a dermatology report, showing our new design.

The broken lines in the drawing represent portions of the computer display panel and the graphical user interface that form no part of the claimed design. The difference in crosshatch shading indicates a contrast of appearance and does not depict any particular color.

1 Claim, 2 Drawing Sheets



(58) **Field of Classification Search**
CPC H04N 21/4884; H04N 21/4888; H04N 21/4856; H04N 21/485; H04N 21/6547
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,921,396	A	7/1999	Brown, Jr.	
D424,541	S *	5/2000	Mugura	D14/486
D430,120	S *	8/2000	Yasui	D14/488
6,106,732	A	8/2000	Johnston et al.	
6,176,836	B1	1/2001	Trudil et al.	
6,447,463	B1	9/2002	Borkowski	
6,720,145	B2	4/2004	Rheins et al.	
D504,440	S *	4/2005	Luquet	D14/486
6,949,338	B2	9/2005	Rheins et al.	
7,183,057	B2	2/2007	Benson	
7,297,480	B2	11/2007	Vogt	
D570,857	S *	6/2008	Nguyen	D14/485
7,921,999	B1	4/2011	Kimball	
7,989,165	B2	8/2011	Benson	
D673,166	S	12/2012	Mori et al.	
8,541,170	B2	9/2013	Kennedy et al.	
8,938,684	B2 *	1/2015	Guertler	G06F 3/0482 715/764
9,057,109	B2	6/2015	Chang	
D786,282	S *	5/2017	Donnelly	D14/486
D788,142	S *	5/2017	Burke	D14/486
D816,697	S *	5/2018	Ledford	D14/486
D816,699	S *	5/2018	Ledford	D14/486
D816,700	S *	5/2018	Bayer	D14/486
D824,402	S *	7/2018	Donnelly	D14/485
D847,840	S *	5/2019	Poschel	D14/486
10,407,729	B2	9/2019	Chang	
D874,474	S *	2/2020	Rognlie	D14/485
10,709,428	B2	7/2020	Palmer et al.	
D900,130	S *	10/2020	Matos	D14/485
D930,010	S *	9/2021	Caudill	D14/485
D944,284	S *	2/2022	Metzger	D14/487
D944,286	S *	2/2022	Sanchez	D14/488
D946,017	S *	3/2022	Courtney	D14/488
11,307,876	B1 *	4/2022	Leonard, II	G06F 9/451
2002/0110824	A1	8/2002	Rheins et al.	
2002/0115086	A1	8/2002	Rheins et al.	
2002/0119471	A1	8/2002	Rheins et al.	
2002/0127573	A1	9/2002	Rheins et al.	
2002/0150918	A1	10/2002	Rheins et al.	
2003/0045810	A1	3/2003	Borkowski	
2006/0242554	A1 *	10/2006	Gerace	G06Q 30/02 715/209
2007/0087323	A1	4/2007	Armitage et al.	
2007/0243537	A1	10/2007	Tuck et al.	
2007/0281314	A1	12/2007	Benson	
2008/0138819	A1	6/2008	Vogt	
2008/0200870	A1 *	8/2008	Palmroos	G06F 3/0488 604/67
2008/0274908	A1	11/2008	Chang	
2010/0086501	A1	4/2010	Chang et al.	
2010/0105102	A1	4/2010	Hanes et al.	
2010/0279877	A1	11/2010	Vogt	
2011/0160080	A1	6/2011	Chang	
2012/0065086	A1	3/2012	Benson	
2013/0296185	A1	11/2013	Benson	
2014/0154684	A1	6/2014	Chang	
2014/0323331	A1	10/2014	Chang et al.	
2015/0005184	A1	1/2015	Alsobrook et al.	
2015/0259739	A1	9/2015	Chang et al.	
2015/0361500	A1	12/2015	Ang et al.	
2016/0024595	A1	1/2016	Alsobrook, II	
2019/0367994	A1	12/2019	Chang	
2020/0149115	A1	5/2020	Dobak et al.	
2020/0289099	A1	9/2020	Palmer et al.	
2020/0308649	A1	10/2020	Dobak et al.	
2020/0308657	A1	10/2020	Dobak et al.	
2020/0319205	A1	10/2020	Dobak et al.	
2020/0383665	A1	12/2020	Palmer et al.	
2020/0407800	A1	12/2020	Dobak et al.	
2021/0196247	A1	7/2021	Palmer et al.	
2021/0198749	A1	7/2021	Chang	
2021/0222246	A1	7/2021	Dobak et al.	
2021/0222247	A1	7/2021	Dobak et al.	
2021/0222258	A1	7/2021	Chang	
2021/0246514	A1	8/2021	Chang	
2022/0162682	A1	5/2022	Dobak et al.	

FOREIGN PATENT DOCUMENTS

WO	WO-2005100603	A2	10/2005
WO	WO-2007124072	A2	11/2007
WO	WO-2008137772	A1	11/2008
WO	WO-2009140550	A2	11/2009
WO	WO-2010025341	A2	3/2010
WO	WO-2010097773	A1	9/2010
WO	WO-2014176446	A1	10/2014
WO	WO-2014210467	A1	12/2014
WO	WO-2016014705	A1	1/2016
WO	WO-2016179043	A1	11/2016
WO	WO-2017165199	A1	9/2017
WO	WO-2018191268	A1	10/2018
WO	WO-2019161126	A1	8/2019
WO	WO-2019183620	A1	9/2019
WO	WO-2019217478	A1	11/2019
WO	WO-2020008192	A2	1/2020
WO	WO-2020198229	A1	10/2020
WO	WO-2020206085	A1	10/2020
WO	WO-2022115487	A1	6/2022

OTHER PUBLICATIONS

Childs. Noninvasive gene expression testing in amelanotic melanoma. JAMA Dermatol 154(2):223-224(2018).
Co-pending U.S. Appl. No. 29/770,783, inventors Dobak; John et al., filed Feb. 16, 2021.
Co-pending U.S. Appl. No. 29/770,784, inventors Dobak; John et al., filed Feb. 16, 2021.
Co-pending U.S. Appl. No. 29/770,785, inventors Dobak; John et al., filed Feb. 16, 2021.
Co-pending U.S. Appl. No. 29/796,477, inventor Dobak; John, filed Jun. 24, 2021.
Dalbe et al. Multiscale Stick-Slip Dynamics of Adhesive Tape Peeling. Phys Rev Lett 115(12):128301 (2015).
De Zotti et al. Bending to Kinetic Energy Transfer in Adhesive Peel Front Microinstability. Phys Rev Lett 122(6):068005 (2019).
Ferris et al. Impact on clinical practice of a non-invasive gene expression melanoma rule-out test: 12-month follow-up of negative test results and utility data from a large US registry study. Dermatology Online J 25(5):pii (May 2019).
Ferris et al. Noninvasive analysis of high-risk driver mutations and gene expression profiles in primary cutaneous melanoma. J Invest Dermatol 139:1127-1134 (2019).
Ferris et al. Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions. Melanoma Res 28(5):478-482 (2018).
Ferris et al. Utility of a noninvasive 2-gene molecular assay for cutaneous melanoma and effect on the decision to biopsy. JAMA Dermatol 153(7):675-680 (2017).
Gerami et al. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. J Am Acad Dermatol 76(1):114-120.e2 (2017).
Hornberger et al. Clinical and economic implications of a noninvasive molecular pathology assay for early detection of melanoma. JAMA Dermatol 154(9):1-8 (2018).
Instructions for use DermTech adhesive skin biopsy kit. DermTech. Available at http://dermtech.com/wp-content/uploads/2015/10/dermtech-ifu-skin-collection-v7.pdf (Revised data Oct. 2015) (1 pg.).
Itoh et al. Generation of 3D skin equivalents fully reconstituted from human induced pluripotent stem cells (iPSCs). PLoS One 8(10):e77673 (2013).

(56) **References Cited**

OTHER PUBLICATIONS

Jansen et al. Gene expression analysis differentiates melanomas from Spitz nevi. J Drugs Dermatol 17(5):574-576 (2018).
Liu et al. Inhibition of p38 MAPK signaling augments skin tumorigenesis via NOX2 driven ROS generation. PLoS One 9(5):e97245 (2014).
Neagu et al. miRNAs in the Diagnosis and Prognosis of Skin Cancer. Front Cell Dev Biol 8:71 (2020) .
PCT/US2016/30287 International Search Report and Written Opinion dated Aug. 16, 2016.
Rivers et al. Non-invasive gene expression testing to rule out melanoma. Skin Therapy Letter 23(5):1-4 (2018).
Rivers et al. Ruling out Melanoma: A practical guide to improving performance through non-invasive gene expression testing. Skin Therapy Letter: Family Practice Edition 14(1):4-6 (2019).
Shen et al., Epigenetic and genetic dissections of UV-induced global gene dysregulation in skin cells through multi-omics analyses. Scientific Reports 7:42646 (2017).
Shen et al., Transcriptome analysis identifies the dysregulation of ultraviolet target genes in human skin cancers. PLoS One 11 (9):e0163054 [1-14] (2016).
Siegel et al. Further consideration of the pigmented lesion assay-reply. JAMA Dermatol 155(3):393-394 (2019).
Thoroddsen et al. Stick-slip substructure in rapid tape peeling. Phys Rev Lett 82(4 Pt 2):046107 (2010).
Torres et al. MicroRNA Ratios Distinguish Melanomas from Nevi. J Invest Dermatol. 140(1):164-173.e7 (2020).
Wachsman et al. Differentiation of melanoma from dysplastic nevi in suspicious pigmented skin lesions by non-invasive tape stripping. Journal of Dermatology 127(Supp 1s):S145 (2007).
Yao et al. An adhesive patch-based skin biopsy device for molecular diagnostics and skin microbiome studies. J Drugs Dermatol 16:979-986 (2017).
Yao et al. Analytical Characteristics of a Noninvasive Gene Expression Assay for Pigmented Skin Lesions. Assay Drug Del Technol 14(6):355-363 (2016).

* cited by examiner

DermTech

P: 858.450.4222 | F: 858.264.2198 | dermtech.com
11388 N. Torrey Pines Road, Suite 100 | La Jolla, CA 92037

PLA (Pigmented Lesion Assay) plus
MOLECULAR PATHOLOGY REPORT

PATIENT INFORMATION

Patient Name:		KMD / Accn ID:	
Reference #:		Body Site:	
MRN #:		Date Collected:	
DOB (Age):		Date Received:	
Sex:		Date Reported:	
Referring Physician:		Fax Number:	
Address:		City/State/Zip:	

TEST RESULTS

GENE EXPRESSION RISK STATUS:	LINC00518: PRAME:
MUTATION RISK STATUS:	TERT Promoter:

Expression of LINC00518 and/or PRAME is found in lesions with a histopathologic diagnosis of melanoma. If one or both of the genes are detected, the test is positive. High Risk driver mutations in the TERT promoter region are found in early cutaneous and metastatic melanoma. The presence of mutations in TERT gene promoter are associated with in situ and invasive melanoma.

Risk Status Interpretation:

- LOW (GREEN): Melanoma-associated gene expression and mutation risk status negative. Consider surveillance per standard of care.
- MODERATE (ORANGE): Positive for LINC00518 alone has a sensitivity of 84%. Positive for PRAME alone has a sensitivity of 83%. Recommend surgical biopsy consistent with AAD treatment guidelines for lesions clinically suggestive of cutaneous melanoma. Consider complete removal to full depth and breadth with clear margins.
- HIGH (RED): Positive for LINC00518 and PRAME combined have a sensitivity of 91%. Recommend surgical biopsy consistent with AAD treatment guidelines for lesions clinically suggestive of cutaneous melanoma. Consider complete removal to full depth and breadth with clear margins.
- Plus(+): Positive for TERT alone has a sensitivity of 73%. TERT promoter mutations convey additional risk and probability of melanoma beyond LINC00518 or PRAME. Consider complete removal to full depth and breadth with clear margins.

FIG. 1



DermTech

P: 858.450.4222 | F: 858.224.2188 | dermtech.com
11099 N. Torrey Pines Road, Suite 100 | La Jolla, CA 92037



PLA (Pigmented Lesion Assay) plus
MOLECULAR PATHOLOGY REPORT

PATIENT INFORMATION

Patient Name:		Kit/ID / Accn ID:	
Reference #:		Body Site:	
MRN #:		Date Collected:	
DOB (Age):		Date Received:	
Sex:		Date Reported:	
Referring Physician:		Fax Number:	
Address:		City/State/Zip:	

TEST RESULTS

GENE EXPRESSION RISK STATUS:	**LINC00518:** **PRAME:**
MUTATION RISK STATUS:	**TERT Promoter:**

Expression of LINC00518 and/or PRAME is found in lesions with a histopathologic diagnosis of melanoma. If one or both of the genes are detected, the test is positive. High Risk driver mutations in the TERT promoter region are found in early cutaneous and metastatic melanoma. The presence of mutations in TERT gene promoter are associated with in situ and invasive melanoma.

Risk Status Interpretation:

	LOW (GREEN): Melanoma-associated gene expression and mutation risk status negative. Consider surveillance per standard of care.
	MODERATE (ORANGE): Positive for LINC00518 alone has a sensitivity of 84%. Positive for PRAME alone has a sensitivity of 83%. Recommend surgical biopsy consistent with AAD treatment guidelines for lesions clinically suggestive of cutaneous melanoma. Consider complete removal to full depth and breadth with clear margins.
	HIGH (RED): Positive for LINC00518 and PRAME combined have a sensitivity of 91%. Recommend surgical biopsy consistent with AAD treatment guidelines for lesions clinically suggestive of cutaneous melanoma. Consider complete removal to full depth and breadth with clear margins.
	Plus(+): Positive for TERT alone has a sensitivity of 73%. TERT promoter mutations convey additional risk and probability of melanoma beyond LINC00518 or PRAME. Consider complete removal to full depth and breadth with clear margins.

FIG. 2